Merck & Co., Inc.

NYSE:MRK

Drug Manufacturers - General

Healthcare
$137.78 -1.14%

-$1.32 today

Market cap
$339.66B
Beta
0.22
P/E (TTM)
31.6
EPS (TTM)
$3.61
Dividend yield
2.94%
52W Low $76.66High $125.14

Volume 9.69M

Average 11.85M

MRK Operating Cash Flow

Cash generated by the company's core business operations during the period.

Merck & Co., Inc.NYSE: MRK

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow growth accelerates

Q2 FY2026 operating cash flow of $5.37B rose 63.1% year over year, ahead of the +7.7% change in trailing-twelve-month operating cash flow. Sequentially, it rose 37.1% from the prior quarter. Over 3 fiscal years it compounded at -4.8% a year.

Context

  • Operating cash flow amounted to 25.4% of revenue in FY2025, down 8.1 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +63.1% holds above the trailing-twelve-month pace of +7.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$5.37B+37.1% QoQ
Last fiscal yearDec 2025
$16.47B-23.3% YoY
LTMJun 2026
$19.97B+7.7% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+63.1%——
1 year-23.3%——
3-year CAGR-4.8%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
16.47B USD
Year-over-year change
-23.3%
4-year CAGR
+3.9%

Operating Cash Flow vs competitors

How MRK compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.7% is the 5th highest of 10, against a peer median of +3.9%.
  • Operating cash flow amounts to 30.1% of revenue for MRK, versus a peer median of 30.3%.
MRK Competitors
Operating Cash Flow for MRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$28.08B USD+156.7%+30.4%35.3%
JNJJohnson & JohnsonLTM Sep 2026$26.16B USD+8.1%+5.0%26.3%
MRKMerck & Co., Inc.LTM Jun 2026$19.97B USD+7.7%-4.8%30.1%
ABBVAbbVie Inc.LTM Jun 2026$19.51B USD+1.2%-8.6%30.3%
NVSNovartis AGLTM Jun 2026$18.39B USD-11.5%+10.6%33.1%
SNYSanofiLTM Jun 2026€14.29B EUR+582.9%+4.8%29.2%
GILDGilead Sciences, Inc.LTM Jun 2026$13.55B USD+37.3%+3.4%44.5%
PFEPfizer Inc.LTM Jun 2026$13.4B USD-11.8%-26.3%21.0%
AZNAstraZeneca PLCLTM Sep 2026$13.33B USD-11.9%+14.1%21.4%
AMGNAmgen Inc.LTM Jun 2026$12.48B USD+3.9%+0.8%32.7%
Peer median (excluding MRK) —+3.9%+4.8%30.3%

Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income12.36B14.53B365M17.13B18.25B
Depreciation & Amortization3.21B3.91B3.87B4.5B5.84B
Deferred Income Tax187M(1.57B)(1.9B)(1.25B)(1.67B)
Stock-Based Compensation479M541M645M761M0
Change in Working Capital(3.84B)(2.78B)(2.21B)(3.67B)(6.98B)
Accounts Receivables(2.03B)(644M)(1.15B)(244M)(1.09B)
Inventory(674M)(161M)(816M)(835M)(1.18B)
Accounts Payables405M(289M)(380M)182M110M
Other Working Capital(1.54B)(1.69B)139M(2.77B)(4.82B)
Other Non-Cash Items1.71B4.47B12.23B3.99B1.03B
Operating Cash Flow14.11B19.1B13.01B21.47B16.47B
Capital Expenditures(4.45B)(4.39B)(3.86B)(3.37B)(4.11B)
Acquisitions (Net)(12.91B)(121M)(12.03B)(4.09B)(10.04B)
Purchases of Investments(1M)(1.2B)(955M)(519M)(1.21B)
Sales of Investments1.03B721M1.66B377M1.68B
Other Investing Activities(225M)32M1.11B(127M)(58M)
Investing Cash Flow(16.56B)(4.96B)(14.08B)(7.73B)(13.74B)
Debt Repayment1.63B(2.25B)4.18B2.31B11.38B
Common Stock Issued0384M0092M
Common Stock Repurchased(840M)0(1.35B)(1.31B)(5.08B)
Dividends Paid(6.61B)(7.01B)(7.45B)(7.84B)(8.18B)
Other Financing Activities8.41B(240M)(203M)(195M)(131M)
Financing Cash Flow2.59B(9.12B)(4.81B)(7.03B)(1.92B)
Effect of Forex Changes(133M)(410M)23M(293M)563M
Net Change in Cash14M4.61B(5.86B)6.41B1.37B
Free Cash Flow9.66B14.71B9.14B18.1B12.36B

Merck & Co., Inc.

NYSE:MRK

Intrinsic Alpha fair value

Locked

Current Price

$137.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.